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A B S T R A C T
Background
Asthma severity and control can be measured both subjectively and objectively. Sputum analysis for evaluation of percentage of sputum
eosinophilia directly measures airway inflammation, and is one method of objectively monitoring asthma. Interventions for asthma
therapies have been traditionally based on symptoms and spirometry.
Objectives
To evaluate the efficacy of tailoring asthma interventions based on sputum analysis in comparison to clinical symptoms (with or without
spirometry/peak flow) for asthma related outcomes in children and adults.
Search methods
We searched the Cochrane Airways Group Specialised Register of Trials, the Cochrane Central Register of Controlled Trials (CEN-
TRAL), MEDLINE, EMBASE and reference lists of articles. The last search was conducted in November 2008.
Selection criteria
All randomised controlled comparisons of adjustment of asthma therapy based on sputum eosinophils compared to traditional methods
(primarily clinical symptoms and spirometry/peak flow).
Data collection and analysis
Results of searches were reviewed against pre-determined criteria for inclusion. Three sets of reviewers selected relevant studies. Two
review authors independently assessed trial quality extracted data. Authors were contacted for further information but none were
received. Data were analysed as “treatment received” and sensitivity analyses performed.
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Main results
Three adult studies were included; these studies were clinically and methodologically heterogenous (use of medications, cut off for
percentage of sputum eosinophils and definition of asthma exacerbation). There were no eligible paediatric studies. Of 246 participants
randomised, 221 completed the trials. In the meta-analysis, a significant reduction in number of participants who had one or more
asthma exacerbations occurred when treatment was based on sputum eosinophils in comparison to clinical symptoms; pooled odds
ratio (OR) was 0.49 (95% CI 0.28 to 0.87); number needed to treat to benefit (NNTB) was 6 (95% CI 4 to 32).
There were also differences between groups in the rate of exacerbation (any exacerbation per year) and severity of exacerbations defined
by requirement for use of oral corticosteroids but the reduction in hospitalisations was not statistically significant. Data for clinical
symptoms, quality of life and spirometry were not significantly different between groups. The mean dose of inhaled corticosteroids per
day was similar in both groups and no adverse events were reported. However sputum induction was not always possible.
Authors’ conclusions
Tailored asthma interventions based on sputum eosinophils is beneficial in reducing the frequency of asthma exacerbations in adults
with asthma. This review supports the use of sputum eosinophils to tailor asthma therapy for adults with frequent exacerbations and
severe asthma. Further studies need to be undertaken to strengthen these results and no conclusion can be drawn for children with
asthma.
P L A I N L A N G U A G E S U M M A R Y
Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults
Pharmacological treatment of asthma is tailored based on various subjective or objective outcome measures. The objective of this review
was to evaluate the efficacy of tailoring asthma interventions based on sputum eosinophils in comparison to clinical symptoms for
asthma related health outcomes in children and adults. Three trials involving 246 adults fulfilled the predetermined criteria but there
were no studies in children. Tailored asthma interventions based on sputum eosinophils is beneficial in reducing the frequency and
severity of asthma exacerbations in adults with asthma. This review supports the use of sputum eosinophils to tailor asthma therapy
only for adults in reducing the frequency and severity of asthma exacerbations. However, as data for clinical symptoms, quality of life
and spirometry were not different between the groups, use of sputum eosinophilia cannot be advocated in all settings until more studies
are available. As there were no studies in children, no recommendation can be made for children with asthma.
B A C K G R O U N D
The severity and control of asthma in both children and adults can
be based on subjective or objective measures. Subjective measures
usually involve a series of questions used for clinical assessment,
diary cards and quality of life questionnaires. Traditional objective
measures include peak flow monitoring, spirometry and degree
of airway hyper-responsiveness (AHR) (Zacharasiewicz 2005).
More recently, markers of airway inflammation (such as sputum
eosinophils, exhaled nitric oxide and breath condensate markers)
have been advocated for asthma monitoring. These may be more
sensitive markers than subjective measures, as they directly mea-
sure airway inflammation, in comparison to traditional objective
measures (Zacharasiewicz 2005).
Analysis of induced sputum provides similar (but not identical)
data to secretions obtained through bronchial wash and bron-
choalveolar lavage. Analysis of induced sputum is a reproducible
method to study airway inflammation in asthma (Bacci 2002).
Sputum analysis is increasingly used as a noninvasive test to de-
termine airway inflammation and may provide useful informa-
tion in the diagnosis and management of asthma. The markers
obtained from induced sputum include cell differential (particu-
larly eosinophils and neutrophils) and eosinophil cationic protein.
In asthmatic patients, the percentage of eosinophils in induced
sputum is significantly higher than that in non-asthmatic patients
(Ohnishi 1998). Neutrophilic airway inflammation has however
also been described in people with asthma (Green 2002a).
Assessing airway inflammation by quantitative measurements in-
stead of subjective data potentially allows the physician to tai-
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lor personal asthma interventions. However, induced sputum and
sputum analysis is labour intensive and not widely available in
non-research laboratories. Hypertonic saline, used to induce spu-
tum may also temporarily increase asthma symptoms. A system-
atic review evaluating the efficacy of tailoring asthma interven-
tions based on sputum analysis (sputum strategy, SS) in compar-
ison with the traditional reliance primarily on clinical symptoms
of asthma (CS) will be useful to guide clinical practice.
O B J E C T I V E S
To evaluate the efficacy of tailoring asthma interventions based
on sputum analysis in comparison to clinical symptoms (with or
without spirometry/peak flow) for asthma related outcomes in
children and adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials comparing adjustment of asthma
medications based on sputumanalysis in comparison to traditional
methods (primarily clinical symptomswith orwithout spirometry/
peak flow).
Types of participants
Children and adults with classical asthma. Exclusion criteria:
eosinophilic bronchitis, asthma related to an underlying lung dis-
ease such as bronchiectasis and chronic obstructive airway disease.
Types of interventions
All randomised controlled trials of adjustment of asthma therapy
based on sputum eosinophils in comparison to clinical symptoms/
spirometry. Trials that included the use of other interventions will
be included if all participants had equal access to such interven-
tions.
Types of outcome measures
Attempts were made to obtain data on at least one of the following
outcome measures.
Primary outcome
a) Proportionof participantswhohad asthma exacerbations during
follow up
Secondary outcomes
b) Mean difference in asthma related outcome measures
c) Proportions experiencing adverse effects of the interventions
d) Proportions experiencing complications, for example, require-
ment for medication change, etc.
The proportions of participants who failed to improve on treat-
ment and the mean clinical improvement were determined using
the following hierarchy of assessment measures (i.e. where two or
more assessment measures are reported in the same study, the out-
come measure that is listed first in the hierarchy was used).
i) Hospitalisation, acute presentations to an emergency facility
for asthma, frequency of exacerbations and rescue courses of oral
corticosteroids.
ii) Symptomatic (quality of life, Likert scale, asthma diary, visual
analogue scale) - assessed by the patient (adult or child).
iii) Symptomatic (quality of life, Likert scale, asthma diary, visual
analogue scale) - assessed by the parents/carers.
iv) Symptomatic (Likert scale, visual analogue scale) - assessed by
clinicians.
v) Indices of spirometry, peak flow, airway hyper-responsiveness.
vi) Beta-agonist used.
Search methods for identification of studies
We identified trials from the following sources:
1. Cochrane Airways Group Specialised Register of Trials;
2. Cochrane Central Register of Controlled Trials
(CENTRAL), The Cochrane Library Issue 4, 2008;
3. MEDLINE (1966 to 2008). Topic search strategy
combined with the RCT search filter as outlined in the Airways
Group module;
4. OLDMEDLINE (1950 to 1965). Topic search strategy
combined with the RCT search filter as outlined in the Airways
Group module;
5. EMBASE (1980 to 2008).Topic search strategy combined
with the RCT search filter as outlined in the Airways Group
module;
6. List of references in relevant publications; and
7. Written communication with the authors of trials included
in the review.
All records in the Airways Group register coded as ’asthma’ were
searched with the following terms: ’sputum* or “airway inflam*”
or mucus or phlegm’. For the full search strategies used in other
databases see Appendix 1.
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Data collection and analysis
Retrieval of studies
From the title, abstract, or descriptors, we reviewed the literature
search independently in triplet (AC reviewed all and two sets of re-
view authors: HP paired with AL; AK paired with CT) to identify
potentially relevant trials for full review. We searched bibliogra-
phies and texts to identify additional studies. From the full text us-
ing specific criteria, the same sets of review authors independently
selected trials for inclusion. Agreement was measured using kappa
statistics. There was no disagreement although it was planned that
disagreement would have been resolved by third party adjudica-
tion.
We reviewed trials that satisfied the inclusion criteria and recorded
the following information: study setting, year of study, source of
funding, patient recruitment details (including number of eligible
participants), inclusion and exclusion criteria, other symptoms,
randomisation and allocation concealment method, numbers of
participants randomised, blinding (masking) of participants, care
providers and outcome assessors, dose and type of intervention,
duration of therapy, co-interventions, numbers of patients not fol-
lowed up, reasons for withdrawals from study protocol (clinical,
side-effects, refusal and other), details on side-effects of therapy,
and whether intention-to-treat analyses were possible. Data was
extracted on the outcomes described previously and data from
included studies was double entered into Review Manager 5 for
meta-analysis. Initial attempts to contact the corresponding au-
thors were not successful, but further information may be avail-
able for the next update of this review.
Quality assessment
Two review authors (HP and AC) independently assessed the qual-
ity of the studies included in the review.). We assessed four com-
ponents of quality:
1. Allocation concealment. Trials were scored as: Grade A:
Adequate concealment, Grade B: Unclear, Grade C: Clearly
inadequate concealment. (Grade A = high quality);
2. Blinding. Trials were scored as: Grade A: Participant and
care provider and outcome assessor blinded, Grade B: Outcome
assessor blinded, Grade C: Unclear, Grade D: No blinding of
outcome assessor (Grade A, B = high quality);
3. Reporting of participants by allocated group. Trials were
scored as: Grade A: The progress of all randomised participants
in each group described, Grade B: Unclear or no mention of
withdrawals or dropouts, Grade C: The progress of all
randomised participants in each group clearly not described.
(Grade A = high quality); and
4. Follow up. Trials scored as: Grade A: Outcomes measured
in > 90% (where withdrawals due to complications and side-
effects are categorised as treatment failures), Grade B: Outcomes
measured in 80 to 90%, Grade C: Unclear, Grade D: Outcomes
measured in < 80%. (Grade A = high quality).
While only the allocation concealment quality assessment was dis-
played in the meta-analysis figures, all assessments were included
in the ”Characteristics of included studies’ table. Inter-reviewer
reliability for the identification of high quality studies for each
component was measured by the Kappa statistic.
Each study was assessed using a 1 to 5 scale described by Jadad et
al (Jadad 1996) and summarised as follows:
Was the study described as randomised? (1 = yes; 0 = no);
Was the study described as double blind? (1 = yes; 0 = no);
Was there a description of withdrawals and dropouts? (1 = yes; 0
= no);
Was the method of randomisation clearly described and appropri-
ate? (1 = yes; 0 = no); and
Was the method of double blinding well described and appropri-
ate? (1 = yes; 0 = no).
Statistics
For the dichotomous outcome, we calculated variables of each in-
dividual study, relative and absolute risk reductions using a mod-
ified intention-to-treat analysis when the outcome event is bene-
ficial. If the event is non-beneficial (such as exacerbation), ’treat-
ment received’ analysis was utilised. A modified intention-to-treat
analysis assumes that participants not available for outcome as-
sessment have not improved (and probably represents a conserva-
tive estimate of effect). An initial qualitative comparison of all the
individually analysed studies examined whether pooling of results
(meta-analysis) is reasonable. This took into account differences
in study populations, inclusion/exclusion criteria, interventions,
outcome assessment, and estimated effect size.
We included the results from studies that met the inclusion crite-
ria and reported the outcomes of interest in the subsequent meta-
analyses. The summary weighted risk ratio and 95% confidence
interval (fixed-effect model) were calculated (Cochrane statistical
package, Review Manager version 5). For Rate Ratios of com-
mon events whereby one participant may have more than one
event, generic inverse variance (GIV) was utilised. The Rate Ra-
tios were taken from the published papers and the standard errors
were calculated from confidence intervals or P values published
in the papers. It was planned that for cross-over studies, mean
treatment differences would be calculated from raw data, extracted
or imputed and entered as fixed-effect GIV outcome, to provide
summary weighted differences and 95% confidence intervals. For
cross-over trials, it was planned that only data from the first arm
were included in meta-analysis if data was combined with paral-
lel studies (Elbourne 2002). Numbers needed to treat to benefit
(NNTB) was calculated from the pooled Odds Ratio (OR) and its
95% confidence interval (CI) applied to a specified baseline risk
using an online calculator (Cates 2003). The outcome indices were
assumed to be normally distributed continuous variables so the
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mean difference in outcomes could be estimated (weighted mean
difference). If studies reported outcomes using different measure-
ment scales, we estimated the standardised mean difference. Any
heterogeneity between the study results was described and tested
to see if it reached statistical significance using a chi-squared test.
The 95% CI estimate using a random-effects model was included
whenever there are concerns about statistical heterogeneity. Het-
erogeneity is considered significant when the P value is < 0.10
(Deeks 2005).
In one study (Jayaram 2006) it was unclear whether data was
analysed based on those who completed the study (N = 102) or
based on numbers where data could be analysed (N = 96). We
used the conservative number (N = 96) when appropriate.
Subgroup analysis
We had planned to carry out an a priori sub-group analysis for
adults versus children.
It was planned that sensitivity analyses be done to assess the impact
of the potentially important factors on the overall outcomes:
a) study quality;
b) study size;
c) variation in the inclusion criteria;
d) differences in the medications used in the intervention and
comparison groups;
e) differences in outcome measures;
f ) analysis using random-effects model;
g) analysis by “treatment received”;
h) analysis by “intention-to-treat”; and
i) analysis by study design-parallel and crossover studies.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
From searches conducted in 2005 and 2006, 2502 potentially rel-
evant citations were retrieved from the Cochrane Aorways Group
trials register (2436 from 2005 and 66 from 2006). After assess-
ing the abstracts, 65 papers were obtained for consideration to be
included into review. Forty-one papers were not relevant as treat-
ment was not based on sputum eosinophils. Twenty-one studies
were further excluded for other reasons: the main reason for non-
eligibility based on review criteria was the non-controlled, non-
randomised nature of the respective studies (see table ’Character-
istics of excluded studies’). We contacted one author from an ex-
cluded study to clarify a study mentioned in a review article but
the treatment was not based on sputum eosinophils (Wark 2003).
Another (Bacci 2005) was an abstract and we contacted the author
for further information but have not received a reply. Additional
searches in subsequent years (November 2007 and 2008) did not
identify any further studies.
Included studies
Three studies were included (see ’Characteristics of included stud-
ies’ table), one was a multi-centre study (Jayaram 2006) and the
other two were uni-centre studies (Green 2002; Chlumsky 2006).
All studies (Green 2002; Chlumsky 2006; Jayaram 2006) were in
adult patients. There were no studies that included children. Two
studies were double blind, parallel groups (Green 2002; Jayaram
2006) whereas one was single blind, parallel (Chlumsky 2006) and
all were published in English.
In all studies (Chlumsky 2006; Green 2002; Jayaram 2006)
asthma management were based on either clinical strategy/symp-
toms (control arm) or sputum eosinophil strategy (intervention
arm). The control arm in the studies differed slightly; two studies
(Chlumsky 2006; Green 2002) used the British Thoracic Soci-
ety asthma guidelines to base their treatment decisions which in-
cluded traditional assessments of symptoms, peak expiratory flow
and use of beta-2-agonists. The second study (Jayaram 2006) used
symptoms and spirometry to guide the clinical strategy group.
This included daytime symptoms < 4 days per week, night time
symptoms < 1 per week, need for short-acting beta-2-agonists <4
times per week and FEV1 = 80% of the participants personal best.
The intervention arm in the studies, although primarily based on
sputum eosinophil percentage, also differed slightly. In Green et
al’s study, anti-inflammatory treatment was based on maintaining
sputum eosinophil count below 3% with a minimum dose of
anti-inflammatory treatment (Green 2002; Chlumsky 2006). In
Jayaram et al’s study, medications were adjusted to keep sputum
eosinophils to = 2% using inhaled steroids (Jayaram 2006). In
Chlumsky et al’s study, medications were based on maintain the
sputum eosinophil count below 8% (Chlumsky 2006).
The follow up of the three studies also differed: one of the studies
(Green 2002) ran for 12 months with the participants being as-
sessed nine times; Jayaram 2006 ran for two years duration with
monthly visits for one year or at exacerbation, then three monthly
visits or at exacerbations for the second year; and Chlumsky 2006
had a study duration of 18 months with three monthly visits.
Jayaram 2006 defined exacerbations as a loss of symptomatic con-
trol requiring increased use of short acting beta2-agonists by = 4
extra puffs per day for a minimum of 48 hours, or by nocturnal
symptoms, or early morning wakening due to respiratory symp-
toms two or more times in one week. Severe exacerbations were
defined as requiring rescue courses of oral prednisone as defined
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by the investigator. Green 2002 defined severe exacerbations as
a decrease in morning peak expiratory flow to more than 30%
below baseline value on = 2 consecutive days, or deterioration in
symptoms needing rescue course of oral corticosteroid. Chlumsky
2006 defined an exacerbation as a doubling of the frequency of
symptoms or number of puffs of rescue salbutamol or a reduction
in morning PEF by 30% or more on at least two consecutive days
or two of the aforementioned or all three.
Adverse events were not reported in either study. We requested
further information from the authors to allow data to be entered
into RevMan for meta-analysis. None of the authors replied to
requests for further information regarding their published data.
Risk of bias in included studies
Two studies (Green 2002; Jayaram 2006) had Jadad scores of 5,
whereas (Chlumsky 2006) scored 3. In two studies (Green 2002;
Jayaram 2006) blinding, reporting of participants by allocated
group and follow up were of high quality. Allocation concealment
was clearly described in two studies (Green 2002; Chlumsky 2006)
but unclear in the other (Jayaram 2006). Thus one study (Green
2002) scored “high quality” in all four categories and the other
two (Chlumsky 2006; Jayaram 2006) score 3 in the high quality
scale. The agreement between the two sets of review authors was
good (kappa score for Jadad scale was 1.0 and quality assessment
scores was 0.61).
Effects of interventions
The three studies (Green 2002; Chlumsky 2006; Jayaram 2006)
included 246 randomised participants with 221 completing the
trials. However, one study commented that analysis was possible
from an additional six participants (Jayaram 2006).
Asthma exacerbations
All papers (Chlumsky 2006; Green 2002; Jayaram 2006) used
asthma exacerbations as the primary outcome and all described a
significant reduction in various aspects of asthma exacerbations in
the arm that utilised treatment based on sputum eosinophils (SS)
when compared to the clinical symptom (CS) arm (control arm
whereby treatment was based primarily on clinical symptoms). All
studies reported a significant difference between groups in exacer-
bation data with SS group experiencing fewer exacerbations than
the CS group. However, some but not all data that relate to exac-
erbations could be combined for meta-analysis. Also, the defini-
tion of exacerbation of the studies differed; Green and colleagues
used the presence of a severe exacerbation defined as “a decrease
in the morning peak expiratory flow to more than 30% below the
baseline value on two or more consecutive days, or deterioration
in symptoms needing treatment with oral corticosteroids” and did
not report on mild exacerbations (Green 2002). In contrast, Ja-
yaram et al defined exacerbation as “worsening (from control val-
ues) of symptoms requiring increased use of SABAby four or more
extra puffs/day for a minimum of 48 h, or by nocturnal symp-
toms, or early morning wakening due to respiratory symptoms
two or more times in one week, with or without a reduction in
FEV1 of at least 20%” (Jayaram 2006). Chlumsky 2006 defined
an exacerbation as a doubling of the frequency of symptoms or
number of puffs of rescue salbutamol or a reduction in morning
PEF by 30% or more on at least two consecutive days, two of the
aforementioned or all three. The patients were instructed to take
16 mg methylprednisolone each morning for 10 days and to call
the treating physician if they fulfilled the exacerbation criteria.
Outcomes are described below
1. Any exacerbation (Comparison 01)
(a) Number of participants who had one or more exacerbations
(as defined by authors) during the study period (Outcome 01)
Meta-analysis from data combined from all studies showed that
the number of participants experiencing any exacerbation was sig-
nificantly less (P = 0.01) in the SS group than theCS group. Pooled
OR estimate effect was 0.49 (95% CI 0.28 to 0.87; Analysis 1.1).
The NNTB was 6 (95% CI 4 to 32).
(b) Frequency of any exacerbation (per participant-month)
(Outcome 02)
Use of the SS significantly reduced frequency of exacerbations
compared to CS, rate ratio of 0.54 (95% CI 0.37 to 0.78; Analysis
1.2). There was heterogeneity between the studies (I2 = 55%).
(c) Time to first exacerbation
The three studies reported that SS group had significantly longer
time to first exacerbation compared to CS group (Green 2002;
Chlumsky 2006; Jayaram 2006).However, the data from the stud-
ies could not be combined.
2. Exacerbations classified by severity of exacerbation
(Comparison 02)
(a) Hospitalisation (Outcome 01)
None of the participants in Jayaram’s or Chlumsky’s studies were
hospitalised whereas seven in Green’s study were hospitalised.
Combined data showed no difference between the groups (P =
0.08) but favoured the SS group. OR was 0.14 (95% CI 0.02 to
1.25).
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(b) Severe exacerbations requiring rescue oral
corticosteroids (Outcome 02)
Severe exacerbations defined by requirement for rescue oral cor-
ticosteroids, were significantly less in the SS group compared to
the CS group, Rate Ratio of 0.33 (95% CI 0.19 to 0.57), with no
significant heterogeneity between the studies (I2 = 0%, P = 1.0).
(c) Mild exacerbations (Outcome 03)
Data on mild exacerbations were only available in one study
(Jayaram 2006). As the definition of severe exacerbations (other
than that defined in 2a and 2b) differed between the studies, the
data was not combined. Comparing occurrence of exacerbation
types (mild versus severe), there was a significant difference be-
tween groups (Chi2 5.29, df = 1, P = 0.02) suggesting that mild
exacerbations were not reduced as much as severe exacerbations.
3. Eosinophilic Exacerbations (Comparison 03)
Jayaram and colleagues reported types of asthma exacerbations
in each group (Jayaram 2006). Sputum could only be obtained
in 39 of the 47 exacerbations in the SS group and 63 of the 79
total exacerbations in the CS group. Those exacerbations where
sputum could be obtained were classified as eosinophilic or non
eosinophilic and this indicated that the overall reduction in exac-
erbation rate was largely due to a reduction in eosinophilic exac-
erbations in this study.
4. Exacerbations Subgrouped by asthma severity
(Comparison 04)
(a) Any exacerbation (Relative Risk) by severity of asthma
(Outcome 01)
Green and colleagues did not subgroup participants by asthma
severity (Green 2002) nor did Chlumsky 2006. Jayaram and col-
leagues analysed data based on daily requirement for ICS and
LABA. Asthma severity was defined based on minimum daily
maintenance fluticasone (mild asthma = requiring < 250 ug/day;
moderate to severe asthma = requiring = 250 ug/day) (Jayaram
2006).Those with mild asthma (< 250 ug/day fluticasone equiv-
alent) showed no significant difference in Relative risk of exacer-
bation (RR 1.34; 95% CI 0.52 to 3.46). Those with moderate to
severe asthma (= 250 ug/day fluticasone equivalent) also showed
no significant difference between groups in the relative risk (RR)
of exacerbation, although the outcome favoured the SS group (RR
0.63, (95% CI 0.38 to 1.03). The difference between these sub-
group effects was not significant (Chi2 1.93, df = 1, P = 0.19).
(b) Any exacerbations (Relative Risk), by use of long acting
beta2 agonists (LABA) (Outcome 02)
Green and colleagues reported equal numbers of participants in
both groups being treated with LABA (N = 12) but outcomes
based on those on LABA were not available (Green 2002). Data
from Jayaram did not show a significant difference between the
effect on exacerbations in those taking LABA (RR 0.53, 95% CI
0.25 to 1.14) or those not on LABA (RR 1.05, 95% CI 0.62 to
1.78), (Chi2 2.07, df = 1, P = 0.15).
5. Secondary outcomes
Green and colleagues reported other outcomes: nitric oxide was
48% lower in SS group in comparison to CS group at the end of
study. The improvement in methacholine PC20 was significantly
better in the SS group compared to the CS group at 6 months
(doubling doses 1.0 versus -0.7, P = 0.03) and 12 months (0.2
versus -1.3, P = 0.015). However, the visual analogue symptom
scores, total asthma quality of life scores, peak expiratory flow
amplitude (% mean), FEV1 after bronchodilator use and the use
of rescue beta-2-agonists did not differ between the two groups
in Green and colleagues study (Green 2002). Jayaram and col-
leagues did not report these outcomes; although asthma quality
of life (QoL) assessments were undertaken, these results were not
published (Jayaram 2006)]. Chlumsky et al’s study also reported
no difference between groups for FEV1 change and they did not
report on symptoms or QOL (Chlumsky 2006).
6. Mean daily dose of corticosteroid use (Comparison
05)
(a) Inhaled corticosteroid (Outcome 01)
All three studies reported no differences in ICS use between
groups. The SD for the groups were not available in Jayaram’s
paper and was estimated based on the data from Green’s paper.
Forest plots showed no significant difference between the groups.
Pooled WMD 78.99 (95% CI -90.13 to 248.11).
(b) Oral corticosteroids (Outcome 02)
Only Green and colleagues reported on mean oral corticosteroids
use and described no difference between the groups (mean differ-
ence of -0.40, 95% CI -2.36 to 1.56) (Green 2002). Meta-analysis
was not possible.
7. Cost (Comparison 06)
Green and colleagues described estimated cost per patient per year
and there was no significant difference between the groups (mean
difference of -314, 95% CI -941.27 to 313.27) (Green 2002).
Data from the other two studies were not available.
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8. Other results
Sputum induction was not always successful; in Green’s study,
sputum induction was successful in 552 of 632 attempts (87%)
(Green 2002) and 102 out of a total of 126 (81%) in Jayaram and
colleagues’ study (Jayaram 2006). Chlumsky 2006 did not report
their success rate in obtaining sputum. No other adverse events
were reported in the studies.
Sensitivity Analyses
In the outcome of number of participants with one or more ex-
acerbations during the study period (comparison 01.01), analyses
based on ’intention to treat’ (ITT) altered pooledOR only slightly
from 0.49 (95% CI 0.28 to 0.87) for ’treatment received’ to 0.50
(0.28 to 0.88). The NNTB changed from 6 (95% CI 4 to 32)
to 7 (95% CI 4 to 35). Re-analysis of the data based on the less
conservative numbers (i.e. use of total of 102 as opposed to 96)
for Jayaram and colleagues study (Jayaram 2006) did not change
the direction or significance of any of the outcomes. Likewise re-
analysis of data based on ITT did not alter direction or signifi-
cance of effects. In the outcomes described above, significant het-
erogeneity was only found in subgroup comparisons and thus no
sensitivity analyses were performed for this. Also, as there were
only two studies in this review, re-analyses by study quality, size,
etc were not possible.
D I S C U S S I O N
This meta-analysis based on threemoderate to high quality studies
in 246 adults (221 completed) has shown that tailoring asthma
interventions based on a sputum strategy (% eosinophils) in com-
parisonwith usual traditionalmethods (based primarily on clinical
symptoms) is effective in reducing the frequency and the severity
of exacerbations (defined by requirement for rescue oral corticos-
teroids). The NNT to reduce number of participants with one or
more exacerbations was 6 (95% CI 3 to 31). However, the differ-
ence between groups was inconsistently significant for other out-
comes although all favoured the group based on sputum analysis.
The mean dose of inhaled corticosteroids per day was similar in
all groups. In subgroup analysis, significant heterogeneity for ex-
acerbation rate was found between those also on and off LABA (I2
= 69.3%). Significant heterogeneity was also present between rate
of eosinophilic versus non eosinophilic exacerbation but there was
no heterogeneity for participants with mild asthma versus those
with moderate asthma classified according to amount of ICS use
per day.
Asthma management based on sputum eosinophilia was effective
in reducing the number of participants who had one or more ex-
acerbations during the study period. It was also effective in reduc-
ing the number of exacerbations per person and the number of
rescue oral corticosteroids required by the SS group. The effects
of treatment based on sputum eosinophils compared with clinical
symptoms alone are likely to be due to a reduction in eosinophilic
exacerbations (comparison 03.01) rather than non-eosinophilic
exacerbations. Thus the benefit of using sputum eosinophilia to
tailor asthma treatment is arguably limited in settings where neu-
trophilic exacerbations (areas of with high environmental pollu-
tion (Leigh 1999) or viral induced exacerbations (Wark 2002)) are
more frequent than eosinophilic exacerbations. Subgroup analy-
sis from Green 2002 reported that patients with non-eosinophilic
inflammation had a reduction in daily inhaled corticosteroids at
the end of the study in comparison with baseline when using the
sputum strategy. In contrast, the BTS management group had an
increase in daily inhaled corticosteroids. However, there no over-
all reduction in overall mean dose of ICS or oral corticosteroids
(Outcomes 04.01 and 04.02).
There was no significant heterogeneity between the studies for any
of the outcomes of significance although the participants were on
different amounts ofmaintenance dose of ICS at enrolment;Green
et al’s study: mean of 1680 to 1930 ug/person/day budesonide
equivalent (Green 2002); Chlumsky et al’s study: mean 1418 to
1695 ug/person/day budesonide equivalent (Chlumsky 2006) and
that of Jayaram et al’s study was 1000 (Jayaram 2006). Also the
percentage of sputum eosinophilia used to guide therapy differed
significantly, ranging from 2% cut-off in Jayaram’s study to 8%
in Chlumsky’s study. Furthermore the definition of exacerbation
varied between the studies. Thus while statistical heterogeneity
was absent, clinical heterogeneity was arguably present.
Theoretically the use of sputum to guide asthma therapy may
result in significant differences in doses of oral or ICS. This meta-
analysis has shown that there was no significant differences in the
amount of corticosteroids (inhaled or oral) used between the two
groups. Also, Green 2002 reported that the annual cost was not
significantly cheaper in the SS group in comparison to the CS
group.
In contrast to the favourable data in the outcome of exacerbations
that support the use of sputum to guide asthma therapies in adults,
there was a glaring lack of difference between the groups in symp-
toms of asthma (VAS score, QoL and beta agonist use). While
exacerbations are an important outcome, arguably subjective mea-
sures of asthma control are also important. Thus, although this
meta-analysis that has shown that monitoring airway inflamma-
tion through eosinophils in induced sputum is useful in reducing
exacerbations, it is arguable that it cannot be universally advocated.
Furthermore, sputum analysis is restricted to laboratories with spe-
cific expertise in inducing and analysing sputum. Obtaining and
analysing sputum is relatively time consuming (when compared
to exhaled nitric oxide) and is not always successful. Also, it can
be very difficult to obtain satisfactory samples in young children.
Nevertheless use of sputum induction to guide asthma therapy is
most likely to be beneficial in adults with severe asthma and those
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with frequent exacerbations.
Limitations of review
This systematic review is limited to three studieswith only 221 par-
ticipants completing the trials.While the studies shared some com-
mon issues, there are also significant differences, notably, the defi-
nition of asthma exacerbation and cut off for sputum eosinophilia
were different. Green 2002 and Chlumsky 2006 used an ob-
jective measurement to define exacerbations (reduction in peak
flow) whereas Jayaram 2006 utilised subjective symptoms (morn-
ing waking, etc), the cut-off of % sputum eosinophils to alter
therapy, and baseline characteristics. Furthermore, Jayaram 2006
failed to report patients’ subjective data from the asthma quality
of life survey.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The results from this review suggests that tailoring asthma inter-
ventions based on sputum eosinophils instead of primarily on clin-
ical symptoms decreases frequency and severity of asthma exac-
erbations, especially eosinophilic exacerbations. However, as data
for clinical symptoms, QOL and spirometry were not different
between groups, use of sputum eosinophilia cannot be advocated
in all settings until more studies are available. Nevertheless, asthma
interventions based on sputum eosinophils is advocated in adult
patients with severe or frequent exacerbations. As there is no data
on children, no recommendations for or against tailoring asthma
medications based on sputum eosinophilia can be made.
Implications for research
Further RCTs with groups stratified by asthma severity and type of
airway inflammation (eosinophilic or neutrophilic) are required.
The trials need to include children as well as adults. The design of
futureRCT’s should preferably bemulti-centre studies and include
other objective measures of asthma including exhaled nitric oxide
in addition to the sputum analysis and traditional outcomes of
spirometry and peak flow. Subjective outcome measures should
also be determined including scores for asthma control and quality
of life. Analysis of costs and possible adverse events of inhaled
and oral corticosteroids would also provide additional important
information.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chlumsky 2006
Methods An open, prospective, randomised, parallel-group trial comparing standard strategy of asthma severity
assessment (standard strategy) with a strategy based on reducing the number of sputum eosinophils (EOS
strategy) over a period of 18 months
Patients were stratified by dose of inhaled steroids, treatment with systemic steroids and add-on therapy
with inhaled long acting beta-2-agonists and theophyllines
Decisions in EOS strategy was made by an independent physician who was blinded to the patients’ clinical
data and telephoned the subjects within one week after a study visit
There were 4 drop outs (all in standard strategy); 2 withdrew for protocol violation and 2 were lost to
follow-up
The subjects were assessed every 3 months for 18 months.
Participants 55 patients were randomised. Standard strategy N=25, mean age 48 (SD 16), 6 males, 15 females.
EOS strategy N=30, mean age 42 (SD 19), 13 males, 17 females.
Visiting an outpatients department.
Inclusion criteria: FEV1 31-110% predicted, daily dose of inhaled corticosteroid 800-6400ug budesonide
or equivalent, diagnosis of asthma confirmed with bronchodilator response greater than 15% after 200ug
salbutamol and/or diurnal peak expiratory flow variation of >20% on at least 4 of 14 days run-in period.
Exclusion criteria: Current smokers and no upper respiratory tract infections within a month preceding
the study
Interventions The subjects were run-in for 2 weeks and then attended outpatients in the morning at 3 monthly intervals
for the 18 months
Standard strategy arm: treatment decisions were based on morning PEF variation, frequency of daytime
symptoms or short acting beta-2-agonists (SABA) use/week, frequency of night time symptoms or SABA/
week.
EOS strategy: treatment decisions were based on the same as the standard strategy arm plus sputum
eosinophils % of total cell count
Outcomes Primary outcome: rate of asthma exacerbations.
Secondary outcomes: FEV1, post bronchodilator FEv1 and FEV1/inspiratory vital capacity ratio
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes Study investigators unaware as to order of treatment
group assignment (Cochrane grade A)
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Green 2002
Methods Randomised, double blind, parallel study comparing asthma management based on British Thoracic
Society (BTS group) asthma guidelines or by normalising sputum eosinophil count (Sputummanagement
group).
Patients were stratified by number of oral corticosteroids used in the previous 12 months, the baseline
induced sputum eosinophil count and baseline methacholine PC20
Neither the physicians nor the subjects were aware of which group they were randomised to or the
treatment protocol. At completion of the study each participant was asked to guess which group they were
in
There was 14 drop outs, 8 during run in and 6 during follow-up
The study ran for 12 months and the subjects were assessed 9 times
Participants 74 adults randomised from 82 recruited subjects. Sputummanagement group n=37: median age 50, range
19-73, 19 males, 18 females.
BTS management group n=37: median age 47, range 20-75, 21 males, 16 females.
Attending one of 3 specialists clinics at Glenfield Hospital, Leicester, UK
Inclusion: diagnosis of asthma and needed hospital follow-up.
Exclusion: current smokers, had a history of smoking more than 15 packs/year, clinical important co-
morbidity, poor compliance, inadequately controlled aggravating factors e.g. rhinitis or GOR, had severe
asthma exacerbation within 4 weeks of entry
Interventions Outpatient visits were at baseline, month 1, 2, 3, 4, 6, 8, 10, 12.
BTS management group: treatment decisions were based on traditional assessments of symptoms, peak
expiratory flow and use of beta-2-agonists.
Sputum management group: anti-inflammatory treatment was based on maintenance of sputum
eosinophil count below 3% with a minimum dose of anti-inflammatory treatment
Outcomes 1. Number of severe asthma exacerbations
2. Control of eosinophilic airway inflammation measured by the induced sputum eosinophil count
3. Exhaled nitric oxide concentrations
4. Symptom scores (0 to 3 for daytime and nighttime symptoms)
5. Total asthma quality-of-life scores
6. Peak flow amplitude as a proportion of the mean
7. FEV1
8. Changes from baseline of methacholine PC20
9. Drug use
10. Admissions for asthma
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes Study investigators unaware as to order of treatment
group assignment (Cochrane grade A)
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Jayaram 2006
Methods Randomised, double blind, parallel group, effectiveness study. It was a multicentre study over a 2 year
period.
Stratified by duration of the asthmatic symptoms (<=20 years or >20 years), inhaled corticosteroid dose
(equivalent to fluticasone <=500 or >500ug/day) and FEV1 (<=70% or >70% predicted)
Subjects blinded to sputum cell counts. Physicians blinded to sputum cell count in clinical strategy group
Drop outs: 15 drop outs including 5 who were excluded due to protocol violations by investigator
Participants 117 randomised out of 140 approached.
Clinical strategy group n=52;mean age 43.5 (SD 13.9), 15 males, 37 females.
Sputum strategy group n=50; mean age 46 (SD 13.8), 15 males, 35 females.
Attending one of 3 Canadian or 1 Brazilian chest clinic.
Inclusion criteria: symptoms of asthma for a minimum of a year.
Exclusion criteria: not mentioned.
Interventions Clinical strategy: guided by symptoms and strategy
Sputum strategy: dose of inhaled steroid was guided solely by induced sputum eosinophils to keep <2%.
Spirometry and symptoms were used to identify clinical control, exacerbations and other treatment
Outcomes 1. Relative risk reduction for the first exacerbation
2. The length of time without exacerbations
3. Type and severity of exacerbations
4. The usefulness of monitoring sputum cell counts in relation to the overall severity of asthma. Defined
by the minimum dose of inhaled steroid to maintain control
5. The cumulative dose of inhaled steroid needed in Phase 2 adjusted for its duration
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Information not available
BTS: British Thoracic Society; FEV1: Forced expiratory volume in 1 second; N: number; PEF: Peak expiratory flow; SABA: Shory-
acting beta-agonist; SD: standard deviation
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aldridge 2002 Randomised, placebo-controlled, crossover study of terbutaline and budesonide, comparing the changes in
eosinophil counts and ECP in induced sputum and blood. Excluded as treatment was not adjusted according
sputum eosinophil counts
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(Continued)
Foresi 2005 Randomised, double-blind, parallel study treating one group with fluticasone propionate 1000ug/day and
then reducing to 200ug/day in comparison to a fixed dose of fluticasone 200ug/day in the control of bronchial
hyperresponsiveness tomethacholine and eosinophilic inflammation. Excluded as treatment was not adjusted
using sputum eosinophils
Gauvreau 2005 Excluded as treatment was not adjusted according to sputum eosinophils. Randomised, double blind,
crossover study of ciclesonide versus placebo after allergan challenge
Giannini 2000 Excluded as treatment not adjusted according to sputum eosinophil counts. Randomised, double blind,
placebo controlled study of beclomethasone dipropionate versus placebo
Gibson 2001 Randomised, double blind, placebo controlled, crossover trial of single dose of budesonide 2400ug versus
placebo and effect on sputum eosinophils and mast cells in adults with asthma. Excluded as treatment was
not based on sputum eosinophil count
Griese 2000 Non RCT nor treatment based on sputum eosinophil count. Prospective study to assess exhaled nitric oxide
in comparison to clinical symptoms, treatment adjusted using clinical symptoms
Jatakanon 1997 Randomised, double blind, crossover study of budesonide versus placebo. Excluded as treatment not based
on eosinophil count
Jatakanon 1998 Excluded as treatment not based on sputum eosinophils. Randomised into two double blind, placebo con-
trolled studies (1 was parallel study involving 3 groups receiving either budesonide 100ug/day, budesonide
400ug/day or placebo the second was a crossover randomised to receive budesonide 1600ug or placebo
Leigh 2000 Excluded as treatment not adjusted based on sputum eosinophils. RCT of budesonide versus placebo in
patients with mild to moderate asthma who had non-eosinophilic airway inflammation
Lonnkvist 2001 Treatment not adjusted according to sputum eosinophil. RCT of budesonide versus placebo in children with
mild to moderate asthma. Investigated the effect of withdrawing inhaled budesonide on eosinophil count in
blood and eosinophil proteins in serum and urine, and the relationship between these markers and symptoms
of asthma
Meijer 2002 Excluded as treatment not adjusted according to sputum eosinophils. Randomised to either prednisolone
30mg/day, fluticasone propionate 2000ug/day or fluticasone propionate 500ug/day for 2 weeks
Nocker 2000 Randomised parallel group study to evaluate the usefulness of induced sputum as an alternative to bron-
choalveolar lavage. Excluded as treatment not adjusted according to sputum eosinophils
Prehn 2000 Excluded as randomised to serum eosinophil cationic protein levels. A pilot study of 21 asthmatic children,
allocated to receive budesonide 200ug twice daily if ECP between 15-30ug/l or budesonide 400ug twice
daily if ECP >30ug/l
Smith 2005 Randomised, single blind, placebo controlled trial adjusting corticosteroids based on exhaled nitric oxide
versus conventional guidelines. Excluded as treatment not based on sputum eosinophil count
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(Continued)
Van Rensen 1999 Excluded as treatment not based on sputum eosinophil count. Randomised, double blind, placebo con-
trolled parallel study to compare the changes in non-invasive markers (airway hyperresponsiveness, sputum
eosinophils and exhaled nitric oxide) after treatment with inhaled glucocorticosteroids
Wark 2003 Non randomised nor treatment adjusted based on sputum eosinophil count. Review article looking at the
techniques of sputum induction, exhaled gas measurements and blood or serum measures as noninvasive
measures of eosinophilic inflammation
Wilson 2000 Non RCT. Cross sectional study of children to determine the feasibility of sputum induction, repeatability
of sputum eosinophil counts and the correlation to asthma symptoms
Zacharaisiewicz 2005 Non RCT. Prospective, observational study in children using non-invasive measures (exhaled nitric oxide,
induced sputum and exhaled breath condensate) to monitor airway inflammation to result in optimal treat-
ment
Zubovic 2003 RCT using serum eosinophil cationic protein (ECP). Excluded as not using sputum eosinophil. One group
was treated with disodium cromoglycate and the other corticosteroid flunisolide to see the success of anti-
inflammatory treatment by measuring the level of ECP and FEV1
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D A T A A N D A N A L Y S E S
Comparison 1. Any exacerbations
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of subjects who had
one or more exacerbations over
the study period
3 215 Odds Ratio (M-H, Fixed, 95% CI) 0.36 [0.20, 0.64]
2 Occurance of any exacerbation 3 215 Rate Ratio (Fixed, 95% CI) 0.54 [0.37, 0.78]
Comparison 2. Exacerbations subgrouped by severity of exacerbation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Hospitalisations 3 215 Odds Ratio (M-H, Fixed, 95% CI) 0.14 [0.02, 1.25]
2 Severe exacerbations requiring
rescue oral corticosteroids
2 164 Rate Ratio (Fixed, 95% CI) 0.33 [0.19, 0.57]
3 Mild exacerbations 1 Rate Ratio (Fixed, 95% CI) Subtotals only
3.1 Mild exacerbations over
study period
1 96 Rate Ratio (Fixed, 95% CI) 0.83 [0.67, 1.03]
3.2 Severe exacerbations over
study period
1 96 Rate Ratio (Fixed, 95% CI) 0.33 [0.16, 0.70]
Comparison 3. Eosinophilic Exacerbations
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Eosinophilic v Noneosinophilic
exacerbations
1 Relative risk (Fixed, 95% CI) Subtotals only
1.1 Eosinophilic
Exacerbations
1 Relative risk (Fixed, 95% CI) 0.28 [0.10, 0.76]
1.2 Noneosinophilic
exacerbations
1 Relative risk (Fixed, 95% CI) 1.07 [0.62, 1.85]
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Comparison 4. Exacerbations subgrouped by asthma severity
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mild v Severe asthma 1 Relative risk (Fixed, 95% CI) 0.74 [0.48, 1.16]
1.1 Very mild to mild asthma 1 Relative risk (Fixed, 95% CI) 1.34 [0.52, 3.43]
1.2 Moderate to severe asthma 1 Relative risk (Fixed, 95% CI) 0.63 [0.38, 1.04]
2 Use of LABA 1 Relative risk (Fixed, 95% CI) 0.85 [0.55, 1.30]
2.1 LABA 1 Relative risk (Fixed, 95% CI) 0.53 [0.25, 1.14]
2.2 Not on LABA 1 Relative risk (Fixed, 95% CI) 1.05 [0.62, 1.78]
Comparison 5. Dose of corticosteroids used
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean dose of inhaled
corticosteroids per person per
day
3 221 Mean Difference (IV, Fixed, 95% CI) 78.99 [-90.13, 248.
11]
2 Mean daily use of oral
corticosteroids per person per
day
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 6. Cost
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Yearly cost per person (US$) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 Any exacerbations, Outcome 1 Number of subjects who had one or more
exacerbations over the study period.
Review: Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults
Comparison: 1 Any exacerbations
Outcome: 1 Number of subjects who had one or more exacerbations over the study period
Study or subgroup Sputum Eos strategy Clinical Sx strategy Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chlumsky 2006 8/30 14/21 31.0 % 0.18 [ 0.05, 0.61 ]
Green 2002 18/34 26/34 31.4 % 0.35 [ 0.12, 0.98 ]
Jayaram 2006 26/45 37/51 37.6 % 0.52 [ 0.22, 1.22 ]
Total (95% CI) 109 106 100.0 % 0.36 [ 0.20, 0.64 ]
Total events: 52 (Sputum Eos strategy), 77 (Clinical Sx strategy)
Heterogeneity: Chi2 = 1.92, df = 2 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 3.49 (P = 0.00048)
0.1 0.2 0.5 1 2 5 10
Favours Sputum Eos Favours control
Analysis 1.2. Comparison 1 Any exacerbations, Outcome 2 Occurance of any exacerbation.
Review: Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults
Comparison: 1 Any exacerbations
Outcome: 2 Occurance of any exacerbation
Study or subgroup Sputum Eos Clinical Sx log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Chlumsky 2006 30 21 -1.266 (0.5) 14.4 % 0.28 [ 0.11, 0.75 ]
Green 2002 34 34 -1.136 (0.45) 17.7 % 0.32 [ 0.13, 0.78 ]
Jayaram 2006 45 51 -0.343 (0.23) 67.9 % 0.71 [ 0.45, 1.11 ]
Total (95% CI) 109 106 100.0 % 0.54 [ 0.37, 0.78 ]
Heterogeneity: Chi2 = 4.43, df = 2 (P = 0.11); I2 =55%
Test for overall effect: Z = 3.25 (P = 0.0011)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Sputum Eos Favours control
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Analysis 2.1. Comparison 2 Exacerbations subgrouped by severity of exacerbation, Outcome 1
Hospitalisations.
Review: Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults
Comparison: 2 Exacerbations subgrouped by severity of exacerbation
Outcome: 1 Hospitalisations
Study or subgroup Sputum Eos strategy Clinical Sx strategy Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chlumsky 2006 0/30 0/21 Not estimable
Green 2002 1/34 6/34 100.0 % 0.14 [ 0.02, 1.25 ]
Jayaram 2006 0/45 0/51 Not estimable
Total (95% CI) 109 106 100.0 % 0.14 [ 0.02, 1.25 ]
Total events: 1 (Sputum Eos strategy), 6 (Clinical Sx strategy)
Heterogeneity: not applicable
Test for overall effect: Z = 1.76 (P = 0.078)
0.1 0.2 0.5 1 2 5 10
Favours Sputum Eos Favours control
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Analysis 2.2. Comparison 2 Exacerbations subgrouped by severity of exacerbation, Outcome 2 Severe
exacerbations requiring rescue oral corticosteroids.
Review: Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults
Comparison: 2 Exacerbations subgrouped by severity of exacerbation
Outcome: 2 Severe exacerbations requiring rescue oral corticosteroids
Study or subgroup Sputum Eos Clinical log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Green 2002 34 34 -1.11 (0.4) 47.4 % 0.33 [ 0.15, 0.72 ]
Jayaram 2006 45 51 -1.1 (0.38) 52.6 % 0.33 [ 0.16, 0.70 ]
Total (95% CI) 79 85 100.0 % 0.33 [ 0.19, 0.57 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 4.01 (P = 0.000061)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours Sputum Eos Favours control
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Analysis 2.3. Comparison 2 Exacerbations subgrouped by severity of exacerbation, Outcome 3 Mild
exacerbations.
Review: Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults
Comparison: 2 Exacerbations subgrouped by severity of exacerbation
Outcome: 3 Mild exacerbations
Study or subgroup Sputum Eos Clinical Sx log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mild exacerbations over study period
Jayaram 2006 45 51 -0.19 (0.11) 100.0 % 0.83 [ 0.67, 1.03 ]
Subtotal (95% CI) 45 51 100.0 % 0.83 [ 0.67, 1.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.084)
2 Severe exacerbations over study period
Jayaram 2006 45 51 -1.1 (0.38) 100.0 % 0.33 [ 0.16, 0.70 ]
Subtotal (95% CI) 45 51 100.0 % 0.33 [ 0.16, 0.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.89 (P = 0.0038)
Test for subgroup differences: Chi2 = 5.29, df = 1 (P = 0.02), I2 =81%
0.2 0.5 1 2 5
Favours Sputum Eos Favours control
22Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.1. Comparison 3 Eosinophilic Exacerbations, Outcome 1 Eosinophilic v Noneosinophilic
exacerbations.
Review: Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults
Comparison: 3 Eosinophilic Exacerbations
Outcome: 1 Eosinophilic v Noneosinophilic exacerbations
Study or subgroup log [Relative risk] Relative risk Weight Relative risk
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Eosinophilic Exacerbations
Jayaram 2006 -1.27 (0.505) 100.0 % 0.28 [ 0.10, 0.76 ]
Subtotal (95% CI) 100.0 % 0.28 [ 0.10, 0.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.51 (P = 0.012)
2 Noneosinophilic exacerbations
Jayaram 2006 0.068 (0.28) 100.0 % 1.07 [ 0.62, 1.85 ]
Subtotal (95% CI) 100.0 % 1.07 [ 0.62, 1.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Chi2 = 5.37, df = 1 (P = 0.02), I2 =81%
0.001 0.01 0.1 1 10 100 1000
Favours Sputum Eos Favours control
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Analysis 4.1. Comparison 4 Exacerbations subgrouped by asthma severity, Outcome 1 Mild v Severe
asthma.
Review: Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults
Comparison: 4 Exacerbations subgrouped by asthma severity
Outcome: 1 Mild v Severe asthma
Study or subgroup log [Relative risk] Relative risk Weight Relative risk
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Very mild to mild asthma
Jayaram 2006 0.293 (0.48) 22.0 % 1.34 [ 0.52, 3.43 ]
Subtotal (95% CI) 22.0 % 1.34 [ 0.52, 3.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
2 Moderate to severe asthma
Jayaram 2006 -0.462 (0.255) 78.0 % 0.63 [ 0.38, 1.04 ]
Subtotal (95% CI) 78.0 % 0.63 [ 0.38, 1.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.070)
Total (95% CI) 100.0 % 0.74 [ 0.48, 1.16 ]
Heterogeneity: Chi2 = 1.93, df = 1 (P = 0.16); I2 =48%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Chi2 = 1.93, df = 1 (P = 0.16), I2 =48%
0.001 0.01 0.1 1 10 100 1000
Favours Sputum Eos Favours control
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Analysis 4.2. Comparison 4 Exacerbations subgrouped by asthma severity, Outcome 2 Use of LABA.
Review: Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults
Comparison: 4 Exacerbations subgrouped by asthma severity
Outcome: 2 Use of LABA
Study or subgroup log [Relative risk] Relative risk Weight Relative risk
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 LABA
Jayaram 2006 -0.635 (0.393) 31.7 % 0.53 [ 0.25, 1.14 ]
Subtotal (95% CI) 31.7 % 0.53 [ 0.25, 1.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.11)
2 Not on LABA
Jayaram 2006 0.049 (0.268) 68.3 % 1.05 [ 0.62, 1.78 ]
Subtotal (95% CI) 68.3 % 1.05 [ 0.62, 1.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.85)
Total (95% CI) 100.0 % 0.85 [ 0.55, 1.30 ]
Heterogeneity: Chi2 = 2.07, df = 1 (P = 0.15); I2 =52%
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Chi2 = 2.07, df = 1 (P = 0.15), I2 =52%
0.001 0.01 0.1 1 10 100 1000
Favours Sputum Eos Favours control
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Analysis 5.1. Comparison 5 Dose of corticosteroids used, Outcome 1 Mean dose of inhaled corticosteroids
per person per day.
Review: Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults
Comparison: 5 Dose of corticosteroids used
Outcome: 1 Mean dose of inhaled corticosteroids per person per day
Study or subgroup Sputum eos strategy Clinical Sx strategy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Chlumsky 2006 30 1695 (1043) 21 1418 (654) 13.1 % 277.00 [ -189.41, 743.41 ]
Green 2002 34 1660 (1253.65) 34 1705 (1102.05) 9.1 % -45.00 [ -606.06, 516.06 ]
Jayaram 2006 50 840 (494) 52 780 (494) 77.8 % 60.00 [ -131.77, 251.77 ]
Total (95% CI) 114 107 100.0 % 78.99 [ -90.13, 248.11 ]
Heterogeneity: Chi2 = 0.92, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
-1000 -500 0 500 1000
Favours Sputum Eos Favours control
Analysis 5.2. Comparison 5 Dose of corticosteroids used, Outcome 2 Mean daily use of oral corticosteroids
per person per day.
Review: Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults
Comparison: 5 Dose of corticosteroids used
Outcome: 2 Mean daily use of oral corticosteroids per person per day
Study or subgroup Sputum eos strategy Clinical Sx strategy
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Green 2002 34 2.6 (3.5) 34 3 (4.66) -0.40 [ -2.36, 1.56 ]
-4 -2 0 2 4
Favours Sputum Eos Favours control
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Analysis 6.1. Comparison 6 Cost, Outcome 1 Yearly cost per person (US$).
Review: Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults
Comparison: 6 Cost
Outcome: 1 Yearly cost per person (US$)
Study or subgroup Sputum eos strategy Clinical Sx strategy
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Green 2002 34 2768 (1096.22) 34 3082 (1510.22) -314.00 [ -941.27, 313.27 ]
-1000 -500 0 500 1000
Favours Sputum Eos Favours control
A P P E N D I C E S
Appendix 1. Search Strategies
Database Search
MEDLINE 1. exp asthma/
2. exp Bronchial Spasm/
3. asthma$.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
4. wheez$.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
5. bronchospas$.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
6. (bronch$ adj3 spas$).mp. [mp=title, original title, abstract, name of substance word, subject heading word]
7. bronchoconstrict$.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
8. (bronch$ adj3 constrict$).mp. [mp=title, original title, abstract, name of substance word, subject heading word]
9. or/1-8
10. Sputum/
11. sputum$.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
12. mucus$.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
13. phlegm$.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
14. or/10-13
15. 9 and 14
(combined with RCT filter)
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(Continued)
EMBASE 1. exp asthma/
2. Bronchospasm/
3. asthma$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufac-
turer, drug manufacturer name]
4. wheez$.mp. [mp=title, abstract, subject headings, headingword, drug trade name, original title, devicemanufacturer,
drug manufacturer name]
5. bronchospas$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device
manufacturer, drug manufacturer name]
6. (bronch$ adj3 spas$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device
manufacturer, drug manufacturer name]
7. bronchoconstrict$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device
manufacturer, drug manufacturer name]
8. (bronch$ adj3 constrict$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer name]
9. or/1-8
10. exp sputum examination/
11. SPUTUM/
12. sputum$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manu-
facturer, drug manufacturer name]
13. mucus$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufac-
turer, drug manufacturer name]
14. phlegm$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manu-
facturer, drug manufacturer name]
15. or/10-14
16. 9 and 15
(combined with RCT filter)
CENTRAL #1. ASTHMA explode tree 1 (MeSH)
#2. BRONCHIAL SPASM single term (MeSH)
#3. asthma*
#4. wheez*
#5. bronchospas*
#6. (bronch* near spas*)
#7. bronchoconstrict*
#8. (bronch* near constrict*)
#9. (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8)
#10. SPUTUM single term (MeSH)
#11. sputum*
#12. mucus*
#13. phlegm*
#14. (#10 or #11 or #12 or #13)
#15. (#1 and #14)
(No RCT filter required)
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WH A T ’ S N E W
Last assessed as up-to-date: 10 December 2008.
Date Event Description
11 May 2009 Amended Corrected data
H I S T O R Y
Protocol first published: Issue 1, 2006
Review first published: Issue 2, 2007
Date Event Description
12 December 2008 New search has been performed 2008 Searches and edited
1 September 2008 Amended Converted to new review format.
21 November 2007 New search has been performed New studies sought but none found
2 February 2007 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Protocol: Written by HP and AC, reviewed by AL, AK, CT
Review: All participated in selection of studies. HP and AC extracted data, performed analysis and wrote review. AL, AK, CT reviewed
manuscript. TL and CC assisted with analysis.
D E C L A R A T I O N S O F I N T E R E S T
Nil
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S O U R C E S O F S U P P O R T
Internal sources
• Royal Children’s Hospital Foundation, Brisbane, Australia.
External sources
• Australian Cochrane Airways Group Scholarship 2006, Australia.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Eosinophils; Adrenal Cortex Hormones [therapeutic use]; Anti-Asthmatic Agents [∗therapeutic use]; Asthma [∗drug therapy; pathol-
ogy]; Leukocyte Count; Randomized Controlled Trials as Topic; Sputum [∗cytology]
MeSH check words
Adult; Child; Humans
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